CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 300 enrolled
Drug / intervention
Neuropsychological scaleother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03370744
NCT03370744N/ACompleted
CompareCT.gov

Prediction of Cognitive Decline by Neuroimaging Techniques and the Application in Diagnosis and Treatment of Preclinical AD (Sino Longitudinal Study on Cognitive Decline, SILCODE)

XuanwuH 2·observational·Posted Dec 12, 2017·Updated Sep 8, 2023

In Brief

An observational study evaluating Neuropsychological scale for Subjective Cognitive Decline and Preclinical Alzheimer's Disease. Completed, enrolled 300 participants across 1 site.

Detailed Summary

This study is affiliated to Sino Longitudinal Study on Cognitive Decline, SILCODE. To establish models of normal and pathological cognitive aging.To collect the longitudinal data of SCD population, to study the dynamic changes of brain networks so as to explore the progressive mechanisms of AD on brain networks and to construct a high-precision multi-modal model for early diagnosis.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsSubjective Cognitive Decline, Preclinical Alzheimer's Disease
CountriesChina
Collaborators--

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedDec 12, 2017
Enrollment StartMar 15, 2017
Primary CompletionJun 30, 2020
Study CompletionDec 31, 2022
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 8.6 years ago

Interventions

Neuropsychological scaleother

Neuropsychological scale, including mini-mental state examination (MMSE), Montreal cognitive assessment (MoCA), clinical dementia rating scales (CDR) and so on